ReviewMedical oncology (Northwood, London, England)2017
New concepts in embolotherapy of HCC.
Review in Medical oncology (Northwood, London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drug-eluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a randomized, prospective, multicenter phase III trial.Signal transduction and targeted therapy · 2024Trial
- Advances in the Therapeutic Landscape of Hepatocellular Carcinoma: Current Strategies and Future Perspectives.Cancers · 2026Review
- HBV reactivation in HCC patients following TACE: risk factors, antiviral therapy impact, and survival analysis.Frontiers in oncology · 2026Article
- Functional Dose-Volume Analysis Based on a Novel Image Biomarker Derived From Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Predicting Poststereotactic Body Radiation Therapy Liver Function Preservation in Patients With Hepatocellular Carcinoma.Advances in radiation oncology · 2025Article
- Sodium alginate-hyaluronic acid composite particles for doxorubicin delivery: in vitro characterization and cytotoxicity evaluation.BMC research notes · 2025Article
- BioPearl™ doxorubicin microspheres for unresectable HCC: a prospective, single-arm, multicenter study: BIOPEARL-ONE.Future oncology (London, England) · 2025Article
- Application of Nanotechnology in TACE Treatment of Liver Cancer.International journal of nanomedicine · 2025Review
- Functional hydrogels for hepatocellular carcinoma: therapy, imaging, and in vitro model.Journal of nanobiotechnology · 2024Review
- Article
- Multimodality annotated hepatocellular carcinoma data set including pre- and post-TACE with imaging segmentation.Scientific data · 2023Article
- Review
- Emerging Polymer Materials in Trackable Endovascular Embolization and Cell Delivery: From Hype to Hope.Biomimetics (Basel, Switzerland) · 2022Review
- Recent advances and applications of microspheres and nanoparticles in transarterial chemoembolization for hepatocellular carcinoma.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
- A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed byJournal of hepatocellular carcinoma · 2021Article
- Prediction of Hepatocellular Carcinoma Response to Transcatheter Arterial Chemoembolization: A Real-World Study Based on Non-Contrast Computed Tomography Radiomics and General Image Features.Journal of hepatocellular carcinoma · 2021Article
- High lymphocyte‑to‑monocyte ratio is associated with low α‑fetoprotein expression in patients with hepatitis B virus‑associated hepatocellular carcinoma.Molecular medicine reports · 2020Article
- Drug-eluting beads transarterial chemoembolization sequentially combined with radiofrequency ablation in the treatment of untreated and recurrent hepatocellular carcinoma.World journal of gastrointestinal surgery · 2020Article
- Basic embolization techniques: tips and tricks.Acta bio-medica : Atenei Parmensis · 2020Review
- Efficacy evaluation of the combination therapy of sorafenib and transarterial chemoembolization for unresectable HCC: a systematic review and meta-analysis of comparative studies.Annals of translational medicine · 2020Article
- Feasibility of Automated Volumetric Assessment of Large Hepatocellular Carcinomas' Responses to Transarterial Chemoembolization.Frontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related deaths worldwide with rapidly growing incidence rates in the USA and Europe. Despite improving surveillance programs, most patients are diagnosed at intermediate to advanced stages and are no longer amenable to curative therapies, such as ablation, surgical resection and liver transplantation. For such patients, catheter-based image-guided embolotherapies such as transarterial chemoembolization (TACE) represent the standard of care and mainstay therapy, as recommended and endorsed by a variety of national guidelines and staging systems. The main benefit of these therapies is explained by the preferentially arterial blood supply of liver tumors, which allows to deliver the anticancer therapy directly to the tumor-feeding artery while sparing the healthy hepatic tissue mainly supplied by the portal vein. The tool box of an interventional oncologist contains several different variants of transarterial treatment modalities. Ever since the first TACE more than 30 years ago, these techniques have been progressively refined, both with respect to drug delivery materials and with respect to angiographic micro-catheter and image-guidance technology, thus substantially improving therapeutic outcomes of HCC. This review will summarize the fundamental principles, technical and clinical data on the application of different embolotherapies, such as bland transarterial embolization, Lipiodol-based conventional transarterial chemoembolization as well as TACE with drug-eluting beads (DEB-TACE). Clinical data on
Indexed as
Identifiers
28299645What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.